UniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

GlobeNewswireSep 23 07:05 ET

Express News | UniQure Biopharma Granted Orphan Drug Designation For Its 'Adeno-associated Viral Vector Serotype 5 Encoding Human Alpha-galactosidase A' For The Treatment Of Fabry Disease

BenzingaSep 19 11:54 ET

H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsAug 20 07:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target

BenzingaAug 20 06:28 ET

Express News | UniQure Doses First Patient In Phase I/IIa Clinical Trial Of AMT-191 For Fabry Disease

BenzingaAug 15 07:09 ET

UniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Yahoo FinanceAug 3 09:05 ET